Breast Cancer

More than 80% of therapies tested in phase 3 oncology trials did not demonstrate clinically meaningful benefit in extending survival, according to results of a study published in JNCCN — Journal of the National Comprehensive Cancer Network.

Measurement of residual cancer burden served as both an accurate and consistent indicator of prognosis across breast cancer subtypes, according to an analysis of data from the randomized I-SPY2 trial published in JAMA Oncology.

Genetic testing for breast cancer has evolved substantially since its inception nearly 30 years ago, according to a speaker at Chemotherapy Foundation Symposium.

Unemployment appeared associated with a lower likelihood of having health insurance and of being up to date on cancer screening tests, according to results of a study published in Cancer.

In a recent interview, Hanna Y. Irie, MD, PhD, discussed her unconventional career path as both a physician-scientist who runs an active research lab and a medical oncologist.

Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.

Breast cancer screening rates declined within 32 community health centers serving lower-income populations during the COVID-19 pandemic, according to an American Cancer Society study published in Cancer.

Research suggests that the COVID-19 pandemic has disrupted breast cancer screening, diagnosis and treatment.

Recent data revealed that regular peanut and tree nut consumption was associated with higher survival rates among long-term breast cancer survivors, particularly those with higher total energy intake and early-stage cancer.

Black women have the highest mortality rate of all women with breast cancer in the U.S., with a significant number presenting at an earlier age of diagnosis and with more advanced-stage disease.